Who Paid My Doc
Digifab
Drug Toxicity Antidote (Digoxin Toxicity)
NDC 50633-120-11
General payments
$1,009,917
Research payments
$1,116,933
Through program year 2024, $1,009,917 in general payments and $1,116,933 in research payments were reported against Digifab (Toxicity Antidote (Digoxin Toxicity)).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $394,582 | 223 |
| 2024 | Research | $220,328 | 4 |
| 2023 | General | $229,642 | 55 |
| 2023 | Research | $286,461 | 7 |
| 2022 | General | $376,235 | 29 |
| 2022 | Research | $302,626 | 6 |
| 2021 | General | $9,458 | 11 |
| 2021 | Research | $307,518 | 10 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 24 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 21 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
318 general · 27 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.